أرمينيا - الإنجليزية - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi-aventis deutschland gmbh - docetaxel (docetaxel trihydrate) - concentrate for solution for infusion - 20mg/ml

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - leflunomide - arthritis, rheumatoid; arthritis, psoriatic - immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard);active psoriatic arthritis.recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glargine - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children aged two years and above

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glargine - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.,

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

sanofi-aventis deutschland gmbh - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz) - insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. limitations of use insulin glargine is not recommended for the treatment of diabetic ketoacidosis. insulin glargine is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] - in patients with hypersensitivity to insulin glargine or one of its excipients [see warnings and precautions (5.5)] risk summary published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes [see data] . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see clinical considerations] . rats and rabbits were exposed to insulin g

أرمينيا - الإنجليزية - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi-aventis deutschland gmbh - levofloxacin (levofloxacin hemihydrate) - solution for infusion - 5mg/ml

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 150mg

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 75mg